Castle Biosciences (CSTL) Total Current Liabilities (2018 - 2026)

Castle Biosciences has disclosed Total Current Liabilities across 9 years of filings, most recently posting $48.8 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $48.8 million, up 30.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.8 million (up 30.82% YoY), and the FY2025 annual result was $68.7 million, up 39.04% from the prior year.
• Total Current Liabilities came in at $48.8 million for Q1 2026 at Castle Biosciences, down from $68.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $68.7 million in Q4 2025 to a low of $27.5 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $39.5 million (2024), against an average of $41.7 million.
• Across the five-year window, Total Current Liabilities soared 124.83% in 2022 and retreated 23.73% in 2023, its largest moves.
• Castle Biosciences' Total Current Liabilities stood at $36.1 million in 2022, then surged by 31.94% to $47.7 million in 2023, then rose by 3.62% to $49.4 million in 2024, then surged by 39.04% to $68.7 million in 2025, then slipped by 29.0% to $48.8 million in 2026.
• The last three Total Current Liabilities figures came in at $48.8 million (Q1 2026), $68.7 million (Q4 2025), and $55.3 million (Q3 2025), per Business Quant data.